Akeso doses first patient in Phase Ib/II NSCLC trial of HER3 ADC AK138D1 with ivonescimabPUBT·Jul 27 at 09:36 PM09926+0.80%
Nomura Expects AKESO to Swing to Interim Profit of RMB46M, Maintains Buy RatingAASTOCKS News·Jul 26 at 11:59 PM09926+0.80%
Akeso grants 3,603,500 share options at HK$ 99.5 exercise price under employee incentive planPUBT·Jul 26 at 06:52 AM09926+0.80%
Summit Updates Ivonescimab OS Data and US FDA Review TimingCoinLive·Jul 23 at 09:52 AMSMMT-1.79%09926+0.80%
Akeso says press release available on Phase II dosing of AK146D1 with ivonescimab in advanced NSCLCPUBT·Jul 20 at 12:32 AM09926+0.80%
HSI Down 494 pts; HSTI Down 195 pts; MEITUAN Down over 6%; TENCENT Down over 3%; BABA Down over 3%; ABLE DIGITAL Hit New HighsAASTOCKS News·Jul 16 at 11:16 PMTCTZF+0.65%09926+0.80%
Hong Kong stock movement: AKESO fell 11.69%, favorable medical insurance fails to mask valuation pressureHK Stock Alerts·Jul 16 at 10:12 PM09926+0.80%
